科源制药
(301281)
| 流通市值：22.31亿 | | | 总市值：35.09亿 |
| 流通股本：6885.20万 | | | 总股本：1.08亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 111,204,722.41 | 463,716,804.91 | 330,879,995.68 | 237,142,859.74 |
| 营业收入 | 111,204,722.41 | 463,716,804.91 | 330,879,995.68 | 237,142,859.74 |
| 二、营业总成本 | 93,014,492.94 | 415,074,066.11 | 303,707,035.89 | 211,807,312.62 |
| 营业成本 | 54,145,854.92 | 258,433,093.82 | 200,947,386.28 | 140,211,296.13 |
| 税金及附加 | 1,565,657.8 | 6,485,013.69 | 5,543,609.05 | 4,508,633.81 |
| 销售费用 | 18,158,711.4 | 77,154,412.33 | 49,859,949.6 | 34,812,126.39 |
| 管理费用 | 10,291,548.09 | 39,746,611.25 | 27,956,440.65 | 18,408,211.01 |
| 研发费用 | 9,894,134.61 | 35,821,601.19 | 22,354,267.62 | 16,083,468.01 |
| 财务费用 | -1,041,413.88 | -2,566,666.17 | -2,954,617.31 | -2,216,422.73 |
| 其中:利息费用 | 1,690.88 | 36,595 | - | - |
| 其中:利息收入 | 601,650.53 | 3,261,168.28 | 3,241,989.83 | 2,274,302.61 |
| 加:公允价值变动收益 | 90,410.96 | 795,000 | 757,130.57 | 370,109.59 |
| 加:投资收益 | 644,276.71 | 12,142,743.09 | 7,250,793.55 | 5,779,909.8 |
| 资产处置收益 | - | 77,957.39 | 77,957.39 | 77,957.39 |
| 资产减值损失(新) | -310,167.16 | -7,681,351.87 | -3,568,389.39 | -827,106.59 |
| 信用减值损失(新) | 204,648.1 | -1,259,197.57 | 229,847.8 | -307,503.44 |
| 其他收益 | 1,230,401.96 | 15,544,722.03 | 13,859,141.13 | 12,039,029.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 20,049,800.04 | 68,262,611.87 | 45,779,440.84 | 42,467,943.12 |
| 加:营业外收入 | 4,000,321.41 | 72,262.21 | 59,028.52 | 59,027.41 |
| 减:营业外支出 | 402,404.99 | 2,626,359.41 | 2,921,327.9 | 1,789,140.57 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 23,647,716.46 | 65,708,514.67 | 42,917,141.46 | 40,737,829.96 |
| 减:所得税费用 | 580,059.98 | 5,436,652.42 | 3,361,680.37 | 4,710,645.84 |
| 六、净利润 | 23,067,656.48 | 60,271,862.25 | 39,555,461.09 | 36,027,184.12 |
| 持续经营净利润 | 23,067,656.48 | 60,271,862.25 | 39,555,461.09 | 36,027,184.12 |
| 归属于母公司股东的净利润 | 23,084,866.5 | 60,448,711.82 | 39,683,076.25 | 36,091,102 |
| 少数股东损益 | -17,210.02 | -176,849.57 | -127,615.16 | -63,917.88 |
| (一)基本每股收益 | 0.21 | 0.56 | 0.37 | 0.33 |
| (二)稀释每股收益 | 0.21 | 0.56 | 0.37 | 0.33 |
| 九、综合收益总额 | 23,067,656.48 | 60,271,862.25 | 39,555,461.09 | 36,027,184.12 |
| 归属于母公司股东的综合收益总额 | 23,084,866.5 | 60,448,711.82 | 39,683,076.25 | 36,091,102 |
| 归属于少数股东的综合收益总额 | -17,210.02 | -176,849.57 | -127,615.16 | -63,917.88 |
| 公告日期 | 2025-04-25 | 2025-04-11 | 2024-10-25 | 2024-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |